摘要
目的:观察分子靶向治疗对80岁以上高龄晚期肿瘤患者的疗效及不良反应。方法:80岁以上高龄晚期肿瘤患者26例,给予分子靶向治疗,药物包括吉非替尼、厄洛替尼、西妥昔单抗、尼妥珠单抗等,按照常规剂量口服或静脉滴注,直至疾病进展或出现不可耐受的不良反应终止治疗。结果:男性25例,女性1例,Ⅲ期7例,Ⅳ期19例。近期疗效:完全缓解1例(3.85%),部分缓解5例(19.2%),疾病有效率为23.1%,稳定10例(38.5%),进展10例(38.5%),疾病控制率为61.5%。中位疾病进展时间为7.5个月,中位生存时间为15.5个月。不良反应主要为皮疹、胃肠道反应和骨髓抑制,多为I级和Ⅱ级,只有2例患者因严重不良反应终止治疗。结论:靶向治疗对80岁以上高龄晚期患者不失是一种安全有效的方法。
Objective：To investigate the efficacy and toxicity of target therapy in the treatment of elderly patients over 80 years with advanced carcinama. Methods： Twenty six elderly patients over 80 years with advanced carcinama were given target therapy orally or by injection with standard dose which included Gefitinib, Erlotinib,Cetuximab,Nimotuzumab and so on,until the disease progression or intolerable toxicities. Results： All 26 patients （males：females,25∶1;stage III：stageⅣ,7∶19） were analyzed.Complete response rate and partial response rate were 3.85% and 19.2% respectively; effective rate was 23.1%; stability of disease was 38.5%, progression of disease was 38.5%, disease control rate was 61.5 %. Median time to progression and median time of survival was 7.5 months and 15.5 months respectively. The major adverse events were mild to moderate skin rash, gastrointestinal reaction and myelosuppression. Only two cases quitted the treatment because of severe adverse reactions. Conclusion： Target therapy is effective and tolerable for the elderly patients over 80 years with advanced carcinama.
出处
《现代肿瘤医学》
CAS
2010年第9期1834-1837,共4页
Journal of Modern Oncology
关键词
靶向治疗
高龄
晚期肿瘤
target therapy
elderly
advanced carcinama
